Johnson & Johnson ( JNJ) reported that its cancer drug Rybrevant Faspro, combined with immunotherapy and chemotherapy, shrank ...
Genmab presented clinical updates on petosemtamab, an investigational bispecific antibody, in two major solid tumor types at ...
Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab,an investigational ...
Expert and company perspectives on the role of amivantamab in advancing first-line treatment “Patients with recurrent or metastatic head and neck cancer continue to face a poor prognosis, highlighting ...
Beginning survivorship care for head and neck cancer patients earlier is linked to better survival and lower recurrence, ...
A trial has shown a new triple therapy may help to shrink tumours in patients with difficult-to-treat and aggressive cancers.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs i ...
This guide for newly diagnosed patients provides key information to help you understand your options and have informed conversations with your oncologist. A diagnosis of head and neck cancer can bring ...
The 50-patient COMPORT phase II trial will prospectively evaluate whether pathology-based omission of low-risk anatomical compartments can individualize postoperative radiotherapy for head and neck ...
By Dennis Thompson HealthDay ReporterMONDAY, Oct. 26, 2026 (HealthDay News) — Starting survivorship care for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results